Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco

Post time 7 day(s) ago

journal：Clinical Cancer Research

Authors：Eleonora Gariazzo; Arielle Elkrief; Kyle Concannon; Daniele Ognissanti; Alessandra Dodi; Valentina Favorito; Alessandro Di Federico; Andrea De Giglio; Leonardo Brunetti; Valentina Santo; Federica Pecci; Mihaela Aldea; Edoardo Garbo; Joao V. Alessi; Jaclyn LoPiccolo; Francesco Paoloni; Mizuki Nishino; Lynette M. Sholl; Narjust Florez; Julia Rotow; Stacey M. Frumm; Lingzhi Hong; Jianjun Zhang; Don Gibbons; Xinan Wang; Lorenza Landi; Laura Cipriani; Mehrdad Rakaee; Alessio Cortellini; Marcello Tiseo; Federico Cappuzzo; Andrea Ardizzoni; Mark M. Awad; John V. Heymach; Stefano Scalera; Marcello Maugeri-Saccà; Giulio Metro; Natalie Vokes; Adam Schoenfeld; Biagio Ricciuti

Published date：2026-8-14

DOI：10.1158/1078-0432.ccr-25-4793

PDF link：https://aacrjournals.org/clincan ... 789/ccr-25-4793.pdf

Article link：https://doi.org/10.1158/1078-0432.ccr-25-4793

Article Source：American Association for Cancer Research (AACR)。

Remark：

Post time 7 day(s) ago

: This post has been completed
Completed attachments will be deleted within 24 hours.

[AACR] Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[AACR] Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco Copy